CurrentCapital BluecrossPolicy MP 4.033

Diagnosis and Treatment of Dry Eye Syndrome

Defines Capital Blue Cross coverage stance for eyelid thermal pulsation therapy, intense pulsed light with meibomian gland expression, and near-infrared meibography for management of dry eye syndrome (meibomian gland dysfunction) for applicable products and members.

Policy Summary

PayerCapital Bluecross

PolicyDiagnosis and Treatment of Dry Eye Syndrome

Policy CodePolicy MP 4.033

Change TypeNo material changes

Effective DateApr 1, 2025

Next Review DateN/A

Key ActionVerify member benefits and use current procedure codes; expect denial risk for eyelid thermal pulsation, IPL, and meibography as described.

SourceLink

POLICY UPDATE CHANGES

No material clinical or coverage changes in this revision.

Not medically necessaryThermal pulsation & IPL

InvestigationalMeibography

ListedProcedure codes

Multiple RCTs & reviewsEvidence

6Policy history entries

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

Coverage Criteria and Policy Position

Not Medically Necessary / Insufficient Evidence

Policy coverage stance and rationale

Primary coverage stance: Eyelid thermal pulsation therapy and intense pulsed light with subsequent meibomian gland expression are considered not medically necessary for management of dry eye syndrome due to insufficient evidence of health outcome benefit.

Supported by summary of evidence noting limited or inconsistent long-term efficacy and multiple RCTs/observational studies; see policy statement and evidence summary.

Guideline Position (context)

Clinical guideline context

AAO guidance: The American Academy of Ophthalmology's Preferred Practice Pattern indicates thermal pulsation therapy (and formerly commented on IPL) may be considered as a step-two therapy after conservative measures (lid hygiene, environmental/dietary modifications, removal of offending agents, ocular lubricants, etc.) have failed; despite this, the policy classifies these therapies as not medically necessary because evidence is insufficient to demonstrate health outcome benefit.

PPPs referenced and updated (2018 with updates through 2023/2024); comment on IPL was removed in the update.

The existence of this medical policy does not guarantee that a service is a covered benefit under the member's health benefit plan. Benefit determinations are based on the applicable health benefit plan language; medical policies do not constitute a description of benefits. Providers and members should consult the member's health benefit plan or contact Capital Blue Cross for benefit information.

Policy history records a March 25, 2022 minor review during which eyelid thermal pulsation therapy and intense pulsed light (IPL) were changed to not medically necessary. This historical change reflects the policy’s explicit exclusion of these services as of that review.

Eyelid thermal pulsation therapy (e.g., vectored heat-and-pressure systems) and intense pulsed light (IPL) followed by meibomian gland expression are considered not medically necessary for management of dry eye syndrome due to insufficient evidence of improved health outcomes. Procedure codes designated not medically necessary include 0207T and 0563T.

Near-infrared dual imaging of the meibomian glands (high-definition meibography devices such as LipiScan/LipiView) is considered investigational and therefore not covered because there is insufficient evidence that the procedure improves health outcomes. Procedure codes designated investigational include 0330T and 0507T.

The policy history entry dated 03/25/2022 (Minor Review) documents the decision to change eyelid thermal pulsation therapy and IPL to not medically necessary; subsequent consensus reviews (2023 and 2024) note no changes to the policy statements.

Procedural Coding and Coverage Status

Investigational_therefore_not_coveredCPTNot Covered

0330T	Investigational — Procedure Code listed as investigational (therefore not covered) per policy
0507T	Investigational — Procedure Code listed as investigational (therefore not covered) per policy

Not_medically_necessary_therefore_not_coveredCPTNot Covered

0207T	Not medically necessary — Procedure Code listed as not medically necessary (therefore not covered) per policy
0563T	Not medically necessary — Procedure Code listed as not medically necessary (therefore not covered) per policy

Referenced procedure codesCPT

0563T

Procedure code added to policy in 2020 (as recorded in policy history).

What Providers Should Do

Denial Risk

Denial risk: Thermal pulsation, IPL, and Near‑Infrared Meibography

Eyelid thermal pulsation therapy and intense pulsed light (IPL) with subsequent meibomian gland expression are considered not medically necessary for the management of dry eye (Meibomian gland dysfunction) and are therefore not covered. Near‑infrared dual imaging (meibography) is considered investigational and not covered. Providers should expect denial risk when submitting these services without clear coverage criteria.

Not medically necessary / not covered procedure codes: 0207T, 0563T
Investigational / not covered procedure codes: 0330T, 0507T

Documentation Required

Verify benefits and plan documentation

Coverage is determined by the member's specific health benefit plan. The existence of this medical policy does not guarantee coverage for a service. Providers should verify member benefits and prior authorization requirements before scheduling services.

Clinical Background and Evidence Summary

Dry eye syndrome and meibomian gland dysfunction are common causes of ocular irritation and visual disturbance. Treatments range from conservative measures (lid hygiene, warm compresses, ocular lubricants, removal of offending agents) to device-based interventions. Although device therapies such as eyelid thermal pulsation and IPL aim to relieve meibomian gland obstruction, the policy concludes there is insufficient evidence of consistent, meaningful long-term benefit; accordingly these device-based treatments are classified as not medically necessary, and near-infrared meibography is classified as investigational.

Definitions and Device/Procedure Descriptions

Thermal pulsation therapy (e.g., LipiFlow) — device-based treatment description

DefinitionDevice-based treatment that delivers controlled heat and pulsatile pressure to the eyelids to liquefy and express obstructed meibomian gland contents (example: LipiFlow System).

MechanismSimultaneous application of regulated temperature and vectored pressure to the eyelid margin with monitoring to protect adjacent ocular structures.

Indication described in sourceUsed for management of meibomian gland dysfunction to assist in expressing gland blockages when conservative measures have limited efficacy.

Regulatory status referencedLipiFlow was cleared as a Class II 510(k) medical device (described as a vectored thermal pulsation system).

Intense pulsed light (IPL) — application and typical follow-up manual expression

Definition

Policy Summary

PayerCapital Bluecross

PolicyDiagnosis and Treatment of Dry Eye Syndrome

Policy CodePolicy MP 4.033

Change TypeNo material changes

Effective DateApr 1, 2025

Next Review DateN/A

Key ActionVerify member benefits and use current procedure codes; expect denial risk for eyelid thermal pulsation, IPL, and meibography as described.

SourceLink

On This Page

Check the member's benefit plan language for coverage determinations
Contact Capital BlueCross Customer Service or use payer portals for benefit verification and prior authorization status

Prior Authorization

Coding and authorization guidance

Procedure codes listed in the policy are for informational and administrative purposes only; identification of a code in the policy does not imply coverage. Use current, valid codes when billing and follow any prior authorization rules.

Policy coding lists may change — review policy history for coding updates (e.g., 0563T added in 2020)
Bill using current CPT/HCPCS codes and modifier conventions; ensure documentation supports the level of service billed

Step Therapy

Step therapy context and documentation

Thermal pulsation therapy and IPL are considered step‑two therapies by the American Academy of Ophthalmology — after conservative measures have failed — but Capital BlueCross policy deems these services not medically necessary. Document prior conservative therapy attempts if pursuing authorization or appeals.

Conservative (step-one) measures include: lid hygiene, environmental/dietary modifications, removal of offending agents, ocular lubricants, tear conservation, patient education, and prescription drugs
Document trial and failure of conservative therapies when seeking authorization or during appeals

Billing Rule

Coding updates and administrative denial risk

Administrative coding updates in the policy history may affect billing and authorization. Failure to use the current code set or to follow updated billing guidance may lead to claim denials.

Recent policy history notes administrative code additions and reviews (e.g., 0563T added 01/01/2020)
Confirm prior authorization requirements if codes are newly introduced or repurposed

Application of broad-spectrum pulsed light (approximately 550–1200 nm) across the eyelids to produce a warming effect, frequently followed by manual expression of the meibomian glands.

Typical adjunct procedureManual/meibomian gland expression is often performed after IPL application to evacuate liquefied gland contents.

Intended effectWarming of eyelid tissue to aid liquefaction of meibomian secretions and reduce gland obstruction, as described in clinical reports and studies.

Near-infrared dual imaging / meibography — imaging technique (LipiScan/LipiView)

TechniqueImaging using transillumination with a proprietary near-infrared light source to produce high-definition images of meibomian gland structure (examples: LipiScan, LipiView).

PurposeOffice screening tool to identify patients with meibomian gland dysfunction and to evaluate refractive or cataract surgery candidates for coexisting MGD.

Imaging methodUses a transilluminator that everts the eyelid and applies near-infrared illumination to visualize gland morphology for clinical assessment.

Intense Pulsed Light (IPL) — supplemental definition referencing studies and reviews

DescriptionIntense Pulsed Light (IPL) is a light-based therapy applied to the eyelids for meibomian gland dysfunction; multiple RCTs, systematic reviews, and Cochrane reviews are cited in the literature.

Evidence summaryReferences include clinical studies and systematic reviews evaluating safety and efficacy (examples: Rong et al. 2018; Liu et al. 2017; several systematic reviews and a Cochrane review listed).

Clinical contextAlthough some studies report benefit, the policy notes evidence is limited or of low quality and overall clinical benefit remains uncertain.

Eyelid thermal pulsation (e.g., LipiFlow) — supplemental definition referencing systematic and Cochrane reviews

DescriptionEyelid thermal pulsation (e.g., LipiFlow) is a vectored thermal pulsation system designed to clear meibomian gland obstruction by applying controlled heat and pressure.

Evidence baseSystematic reviews and a recent Cochrane review are cited evaluating LipiFlow and vectored thermal pulsation systems (examples: Hu et al. 2021; Pucker et al. 2024 Cochrane review).

Clinical noteWhile individual studies report improvements, systematic reviews highlight limitations in the strength and duration of benefit, contributing to the policy's determination of insufficient evidence for coverage.